Literature DB >> 21743970

Chemotherapy-induced modification of microRNA expression in esophageal cancer.

Richard Hummel1, Tingting Wang, David I Watson, Michael Z Michael, Mark Van der Hoek, Joerg Haier, Damian J Hussey.   

Abstract

Neoadjuvant chemotherapy is often used in the treatment of advanced esophageal cancer. In this study, we determined the impact of chemotherapy on microRNA (miRNA) expression in esophageal cancer cells, and whether identified changes might have biological relevance. Two esophageal carcinoma cell lines (one adenocarcinoma and one squamous cell carcinoma) were treated with cisplatin or 5-fluorouracil for 24 or 72 h. RNA was extracted from cells following 24-h treatment, and used for microarray studies. Promising miRNA candidates were selected for RT-PCR validation. Target prediction using TargetScan, combined with bioinformatic analysis (Ingenuity Pathway Analysis, IPA), was performed to evaluate the implications of the altered miRNA expression. Thirteen miRNAs (miR-199a-5p, miR-302f, miR-320a, miR-342-3p, miR-425, miR-455-3p, miR-486-3p, miR-519c-5p, miR-548d-5p, miR-617, miR-758, miR-766, miR-1286) were deregulated after 24- and/or 72-h treatment in both cell lines, and most miRNAs presented similar expression changes after short- or long-term exposure. IPA revealed that the major networks which incorporate the predicted targets, include functions such as 'Cell death', 'Cell cycle', 'Cellular growth and proliferation', 'DNA replication, recombination, and repair' and 'Drug metabolism'. Cisplatin or 5-fluorouracil alter miRNA expression in esophageal cancer cells. IPA suggests that these miRNAs may target molecular pathways involved in cell survival after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743970     DOI: 10.3892/or.2011.1381

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  49 in total

1.  Bottlenecks caused by software gaps in miRNA and RNAi research.

Authors:  Sean Ekins; Ron Shigeta; Barry A Bunin
Journal:  Pharm Res       Date:  2012-02-24       Impact factor: 4.200

2.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

Review 3.  The role of microRNAs in cancers of the upper gastrointestinal tract.

Authors:  Shumei Song; Jaffer A Ajani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

Review 4.  MicroRNAs and DNA damage response: implications for cancer therapy.

Authors:  Yemin Wang; Toshi Taniguchi
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

5.  Temporal- and strain-specific host microRNA molecular signatures associated with swine-origin H1N1 and avian-origin H7N7 influenza A virus infection.

Authors:  Emma-Kate Loveday; Victoria Svinti; Sandra Diederich; John Pasick; François Jean
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

6.  SNMFSMMA: using symmetric nonnegative matrix factorization and Kronecker regularized least squares to predict potential small molecule-microRNA association.

Authors:  Yan Zhao; Xing Chen; Jun Yin; Jia Qu
Journal:  RNA Biol       Date:  2019-11-27       Impact factor: 4.652

Review 7.  The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.

Authors:  Leonidas Benetatos; Eleftheria Hatzimichael; Eric Londin; George Vartholomatos; Phillipe Loher; Isidore Rigoutsos; Evangelos Briasoulis
Journal:  Cell Mol Life Sci       Date:  2012-07-24       Impact factor: 9.261

8.  Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.

Authors:  Ying-Ying Jin; Qing-Juan Chen; Kun Xu; Hong-Tao Ren; Xing Bao; Yi-Nan Ma; Yang Wei; Hong Bing Ma
Journal:  Mol Cell Biochem       Date:  2016-09-19       Impact factor: 3.396

Review 9.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

10.  Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Authors:  Kirsten Lindner; Christiane Borchardt; Maren Schöpp; Anja Bürgers; Christian Stock; Damian J Hussey; Jörg Haier; Richard Hummel
Journal:  J Exp Clin Cancer Res       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.